JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Pramiracetam is a nootropic drug [1].
Pramiracetam is investigated for its cognition-enhancing properties. A lower dosage of pramiracetam (100 mg/kg i.p.) was inadequate on NOS mRNA expression and chemical action. Interestingly, organization of pramiracetam (300 mg/kg i.p.) in rats pretreated (24 h before) with lithium chloride (LiCl) (3 mEq/kg i.p.) yielded a 40% expansion in cortical NOS action. Be that as it may, in LiCl-pretreated rats this nootropic neglected to influence cortical NOS mRNA expression; LiCl (3 mEq/kg i.p.) given alone delivered no impact. In summary, the present information show that pramiracetam given alone or in blend with LiCl builds NOS movement in mind cortical homogenates of rats and this might add to the components fundamental learning and memory change created by this nootropic. [1]
Antidementia viability of pramiracetam in 10 patients with likely Alzheimer's sickness was assessed utilizing a 2-phase, placebo-controlled, enhancement-type trial design. Eight patients prove a best dosage in the measurement finding stage, however in the ensuing replication stage just two again enhanced to a comparable degree. PETs with fluorodeoxyglucose got in two people demonstrated no distinct change. Dosages up to 4,000 mg pramiracetam are unrealistic to give symptomatic advantage to Alzheimer's infection patients. [2]
References:Systemic administration of pramiracetam increases nitric oxide synthase activity in the cerebral cortex of the rat. Funct Neurol. 1995 May-Jun;10(3):151-5.Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam. Neurology. 1991 Apr;41(4):570-4.